Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 14, 2026 08:00 ET | Source: GeneCentric Therapeutics Inc

GeneCentric to Present Data on Fragmentomics-Based ExpressCT™ Liquid Biopsy Technology at AACR 2026

GeneCentric will present new data on its fragmentomics-based ExpressCT™ liquid biopsy technology at AACR 2026.
April 14, 2026 08:00 ET | Source: Rivus Pharmaceuticals, Inc.

Rivus Pharmaceuticals Announces First Patients Dosed in AMPLIFY Phase 2 Trial for HU6 in MASH

Rivus Pharmaceuticals Announces First Patients Dosed in AMPLIFY Phase 2 Trial for HU6 in MASH
April 14, 2026 04:21 ET | Source: Research and Markets

2 Day Virtual Protein Engineering for Pharmaceutical Biotechnology Course: Understand How to Advance Therapeutic Development and Industrial Applications (ONLINE EVENT: July 7th - July 8th, 2026)

Dublin, April 14, 2026 (GLOBE NEWSWIRE) -- The "Protein Engineering for Pharmaceutical Biotechnology (July 7th - July 8th, 2026)" training has been added to ResearchAndMarkets.com's...
April 13, 2026 16:05 ET | Source: TheRas, Inc. (d/b/a BBOT)

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
April 13, 2026 08:06 ET | Source: Keiretsu Forum Mid-Atlantic

Vetted Deal Flow Takes Center Stage at ACA Summit Innovation Funders Showcase

Keiretsu Forum-MST will present eleven rigorously vetted, investor-ready companies at the 2026 ACA Innovation Funders Showcase, offering curated deal flow
April 13, 2026 07:45 ET | Source: NervGen Pharma Corp.

NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference

VANCOUVER, British Columbia, April 13, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class...
April 13, 2026 07:30 ET | Source: MediWound Ltd.

Newly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound Debridement

Newly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound Debridement Peer-reviewed consensus redefines debridement from simple tissue removal to a more comprehensive...
April 09, 2026 08:00 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026

– Additional Phase 1b data for ABI-5366, including results from monthly dosing cohort, selected for oral presentation –– Phase 1b data from ABI-1179 accepted for late-breaker poster presentation...
April 08, 2026 09:15 ET | Source: USA News Group

The Credibility Filter Wall Street Uses to Sort Biotech Winners

VANCOUVER, British Columbia, April 08, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary — Biotechs that went public in Q1 2026 raised a median of $287.5 million each; and nearly every one...
April 08, 2026 07:00 ET | Source: Immusoft

Immusoft Announces Presentation of World's First Patient Treated with an Engineered B Cell Therapy at Workshop Co-Hosted by FDA and ARM

SAN FRANCISCO, April 08, 2026 (GLOBE NEWSWIRE) -- Immusoft of CA, a clinical-stage biotechnology company pioneering engineered B cell therapies, today announced that it will present an invited...